Naomi (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol, the active ingredient in Naomi, is a combined estrogen‑progestogen oral contraceptive presented as an oral tablet for oral use. It is indicated for prevention of pregnancy in women of reproductive age. GNH USA supplies Naomi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naomi is a combined estrogen‑progestogen oral contraceptive that works within the hormonal birth‑control pathway. - Prevention of pregnancy: provides reliable contraception for women of child‑bearing potential. - Oral contraceptive: delivers a regulated dose of estrogen and progestogen to inhibit ovulation. - Menstrual cycle regulation: helps achieve more predictable menstrual bleeding patterns.

Adverse reactions may occur with any hormonal contraceptive.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort of the breasts. - Spotting or irregular bleeding: breakthrough bleeding between periods. - Mood changes: irritability or emotional fluctuations.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to lung vessels. - Stroke: cerebrovascular accident due to clot or hemorrhage.

Before prescribing Naomi, clinicians should evaluate individual risk factors and counsel patients accordingly. - Cardiovascular risk assessment: avoid in women with history of thromboembolic disease. - Smoking restriction: do not use in smokers over 15 cigarettes per day. - Liver disease review: contraindicated in severe hepatic impairment. - Pregnancy category: X – must not be used during pregnancy. - Blood pressure monitoring: check regularly in hypertensive patients. - Store below 25°C: keep in the original pack, protect from moisture.

Naomi can interact with other medicines that affect hormone metabolism or clotting pathways.

Major Interactions (Avoid): - Enzyme‑inducing antiepileptics (e.g., carbamazepine): reduce contraceptive efficacy. - Rifampicin: markedly decreases hormone levels. - St. John’s wort: may lead to breakthrough bleeding.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole): may increase hormone concentrations. - Selective serotonin reuptake inhibitors (SSRIs): possible alteration of bleeding pattern. - Diuretics: may affect fluid balance and blood pressure control.